Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Olanza 10 - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Olanza 10

Approved

STANDARD

Olanza 10

Unison Laboratories Co., Ltd.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: c2d33f7a22948604
Company: Unison Laboratories Co., Ltd.
Type: Standard

Approval Details

Approval Id: c2d33f7a22948604
Drug Approval Philippines Name: Olanza 10
Product Name: Olanza 10
Registration Number: DR-XY44545
Brand Name: Olanza 10
Generic Name: Olanzapine
Dosage Form: Film Coated Tablet
Dosage Strength: 10 mg
Manufacturer: Unison Laboratories Co., Ltd.
Importer: JustRight Healthcare Inc.
Distributor: JustRight Healthcare Inc.
Issuance Date: 27 October 2024
Expiry Date: 14 May 2030
Pharmacologic Category: Antipsychotic
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

c2d33f7a22948604

Type

Standard

Back to Philippines FDA Approvals